1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Regulation

AAM Urges Action On Product Hopping And Patent Thickets

 
• By Akriti Seth

The AAM’s senior vice-president, Jeffrey Francer, has offered suggestions to US lawmakers on how to curb anti-competitive tactics used by originators.

Red_Arrow_Stethoscope
The AAM’s Jeffrey Francer has thrown light on how originators game the system • Source: Shutterstock

The Association for Accessible Medicines has urged US lawmakers to take action on originator tactics used to “game the system”, including ‘product hopping’ and biosimilar patent thickets used to deter competition.

Testifying before a House of Representatives subcommittee on consumer protection and commerce, AAM senior vice-president Jeffrey Francer said that “current market realities and anti-competitive tactics – combined with misguided

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Medicines UK Welcomes NHS England’s Best-Value Biologics Biosimilar Adoption Framework

 
• By Adam Zamecnik

Reflecting on recent initiatives by NHS England and the MHRA, the newly renamed trade body Medicines UK has welcomed efforts in promoting the use of biosimilars in Britain.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.